Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Guardant Health Inc is a diagnostics & research business based in the US. Guardant Health shares (GH) are listed on the NASDAQ and all prices are listed in US Dollars. Guardant Health employs 1,373 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $43.66 |
|---|---|
| 52-week range | $27.65 - $133.82 |
| 50-day moving average | $43.39 |
| 200-day moving average | $76.90 |
| Wall St. target price | $117.73 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-4.13 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $43.66 from 2022-07-01
| 1 week (2022-06-29) | 3.85% |
|---|---|
| 1 month (2022-06-02) | N/A |
| 3 months (2022-04-06) | -39.45% |
| 6 months (2022-01-06) | -51.62% |
| 1 year (2021-07-06) | -64.86% |
|---|---|
| 2 years (2020-07-06) | -48.78% |
| 3 years (2019-07-05) | 86 |
| 5 years (2017-07-02) | N/A |
| Revenue TTM | $391.1 million |
|---|---|
| Gross profit TTM | $250.7 million |
| Return on assets TTM | -11.78% |
| Return on equity TTM | -55.66% |
| Profit margin | -107.2% |
| Book value | $5.23 |
| Market capitalisation | $4.4 billion |
TTM: trailing 12 months
We're not expecting Guardant Health to pay a dividend over the next 12 months.
Over the last 12 months, Guardant Health's shares have ranged in value from as little as $27.65 up to $133.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Guardant Health's is 0.7226. This would suggest that Guardant Health's shares are less volatile than average (for this exchange).
Guardant Health, Inc. , a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
